TrialThe Lancet. Oncology2022

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.

B Ashleigh Guadagnolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.